MAP2K7 and pneumocystosis: This small, single-arm study demonstrated that 15 patients achieved a partial response or better with vemurafenib–cobimetinib combination therapy, suggesting that BRAF–MEK inhibitors may represent an effective treatment option for PCP patients who have not undergone radiotherapy.